Abiomed (ABMD) Gets a Sell Rating from Morgan Stanley

By Ryan Adsit

Morgan Stanley analyst David Lewis maintained a Sell rating on Abiomed (ABMDResearch Report) today and set a price target of $152.00. The company’s shares closed last Friday at $188.25.

According to TipRanks.com, Lewis is a 5-star analyst with an average return of 8.3% and a 63.1% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Baxter International.

Abiomed has an analyst consensus of Hold, with a price target consensus of $196.00.

See today’s analyst top recommended stocks >>

Abiomed’s market cap is currently $8.62B and has a P/E ratio of 31.80. The company has a Price to Book ratio of 7.64.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded in 1981 and is headquartered in Danvers, MA.